Peter Attia· MD
and to some extent that holds true for apoc3 although apoc3 at extremes of measurements is more predictable and could be useful toward understanding residual risk and metabolic diseases but apoe is more elusive
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and to some extent that holds true for apoc3 although apoc3 at extremes of measurements is more predictable and could be useful toward understanding residual risk and metabolic diseases but apoe is more elusive
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.